Summary: While Major Depressive Disorder (MDD) and Bipolar Disorder (BD) share overlapping symptoms, a novel study reveals distinct biological pathways for each. The research is the first to identify a specific link between metabolic dysfunction, brain structure, and cognition, with these effects being significantly stronger and more specific in patients with Bipolar Disorder.
These findings suggest that addressing insulin and leptin resistance could be a key to treating the persistent cognitive challenges that remain even after a patient’s mood has stabilized.
Key Research Findings
- Disease-Specific Pathways: Metabolic alterations, specifically insulin resistance and leptin dysregulation, were linked to cognitive deficits only in patients with Bipolar Disorder.
- The Metabolic Profile: Patients with BD exhibited a more severe metabolic profile than those with MDD. This dysfunction was closely tied to the “illness burden,” meaning a higher number of manic and mood episodes correlated with worse metabolic health.
- Brain Structure Impact: Metabolic issues were associated with reduced gray matter volume in key brain regions. This structural change is believed to be the bridge leading to poorer performance in memory, attention, and executive function.
- Persistent Symptoms: The study explains why cognitive symptoms often persist even when mood symptoms improve: metabolic health continues to influence brain structure and neural communication independently of active mood episodes.
- Neuroprogressive Model: The findings support a model where repeated mood episodes drive cumulative neurobiological and metabolic changes, emphasizing the need for early intervention.
Source: Elsevier
While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major depressive disorder are distinct.
A novel study appearing in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, published by Elsevier, is the first to identify clinically relevant pathways linking metabolic dysfunction, brain structure, and cognition in mood disorders, with stronger and more specific effects observed in bipolar disorder.
It highlights the potential of targeting metabolic pathways to improve cognitive symptoms in bipolar disorder.
Major depressive disorder and bipolar disorder are disabling psychiatric conditions, significantly impairing mood regulation and biological rhythms. Even when a person’s mood is stable, persistent challenges with memory and focus make it hard to function in everyday life. Increasing evidence suggests a strong link between mood disorders and metabolic dysfunction. Conditions such as obesity, diabetes, and insulin resistance are associated with a higher risk of depression, and vice versa.
“Mood disorders are highly heterogeneous, which often delays diagnosis and effective treatment, highlighting the need for more targeted approaches,” explains lead investigator Elena Mazza, PhD, Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy.
“In a cohort of 78 patients with major depressive disorder and 81 with bipolar disorder, we investigated how insulin resistance and related hormones are associated with brain structure and clinical outcomes, with a particular focus on cognitive function, given the critical role of insulin in neuronal communication, learning, and memory.”
Researchers combined metabolic biomarkers, structural brain imaging, and cognitive assessments to examine how metabolic dysfunction relates to brain structure and cognition. They applied a multivariate statistical approach to investigate these relationships and to assess whether they differed between diagnoses.
Patients with bipolar disorder were found to exhibit a more severe metabolic profile, characterized by insulin resistance and leptin dysregulation, likely reflecting a more severe illness course, as greater illness burden—specifically a higher number of mood and manic episodes—was associated with worse metabolic dysfunction and lifetime burden of illness.
Investigators found that metabolic alterations like insulin resistance are associated with cognitive deficits, potentially through their impact on gray matter volume in key brain regions involved in cognitive functioning and are linked to poorer performance in memory, attention, and executive function.
Notably, these associations were observed only in bipolar disorder, suggesting that insulin and leptin resistance may play a key role in linking metabolic dysfunction to cognitive impairment by promoting inflammatory and neurotoxic processes that affect brain structure, particularly in regions supporting cognition.
Editor-in-Chief of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging Cameron S. Carter, MD, University of California Irvine School of Medicine, comments, “Interestingly, the effects of metabolic dysfunction on clinical and neural outcomes were primarily observed in bipolar disorder.
These findings could be consistent with a neuroprogressive model of bipolar disorder, in which repeated episodes may drive not only clinical worsening but also cumulative metabolic and neurobiological changes. This highlights the importance of early and effective intervention to prevent both clinical deterioration and its associated biological consequences.”
The study’s findings point towards a previously unknown, clinically meaningful pathway linking metabolic dysfunction to cognitive impairment in bipolar disorder through its impact on brain structure.
“Beyond traditional antidepressant treatments, interventions aimed at enhancing insulin sensitivity—such as insulin-sensitizing agents or intranasal insulin—have already shown promising cognitive benefits,” notes lead author Laura Raffaelli, PhD candidate, Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, and Vita-Salute San Raffaele University, Milan, Italy.
“More recently, GLP-1 receptor agonists, currently used for metabolic conditions, have gained attention for their potential positive effects on both mood and cognition, representing a promising avenue for future therapeutic development.”
Dr. Mazza concludes, “Our findings highlight that metabolic health is not just a peripheral concern, but a key factor influencing brain structure and cognitive functioning in mood disorders.
“The results of our study help explain why cognitive symptoms often persist even when mood symptoms improve, underscoring the complex interplay between brain and metabolic health. By clarifying these mechanisms, our study opens the door to more personalized treatment strategies that integrate metabolic and psychiatric care.”
Key Questions Answered:
A: Insulin plays a critical role in neuronal communication, learning, and memory. When the body becomes resistant to insulin or leptin, it can promote inflammatory and neurotoxic processes that physically alter brain regions supporting cognition.
A: Potentially. The study highlights that insulin-sensitizing agents and GLP-1 receptor agonists (commonly used for metabolic conditions) are showing promise for improving both mood and cognitive function.
A: Yes. The researchers found that a higher number of mood and manic episodes was associated with worse metabolic dysfunction, creating a cumulative biological “burden” over a patient’s lifetime.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this bipolar disorder and metabolism research news
Author: Eileen Leahy
Source: Elsevier
Contact: Eileen Leahy – Elsevier
Image: The image is credited to Neuroscience News
Original Research: Open access.
“The anterior cingulate cortex modulates pupil-linked arousal” by Laura Raffaelli, Mariagrazia Palladini, Marco Paolini, Sara Poletti, Cristina Lorenzi, Rosa Decorato, Matteo Carminati, Cristina Colombo, Raffaella Zanardi, Francesco Benedetti, and Elena Mazza. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
DOI:10.1016/j.bpsc.2026.02.003
Abstract
Background
Major depressive disorder (MDD) and bipolar disorder (BD) are associated with persistent cognitive deficits, but the biological mechanisms underlying these impairments remain unclear. Metabolic dysfunction, particularly insulin resistance (IR), may contribute to brain structural alterations and cognitive decline.
However, diagnosis-specific metabolic effects on gray matter volumes (GMVs) and cognition have not been fully explored. Partial least squares path modeling was applied to examine associations among metabolic biomarkers, GMVs, and cognitive performance in mood disorders, stratifying by diagnosis.
Methods
A total of 81 inpatients with BD (55 female, 26 male) and 78 inpatients with MDD (45 female, 33 male) underwent neuropsychological evaluation with the Brief Assessment of Cognition in Schizophrenia. T1-weighted magnetic resonance images were processed to extract GMVs. Blood samples were collected to assess metabolic markers.
Results
In the whole sample, the metabolism latent construct negatively predicted both GMV and cognition, with the GMV factor positively affecting cognition. A significant diagnostic difference emerged for the metabolism-to-cognition path (p = .0196). Stratified analyses showed that in BD, metabolism was significantly associated with both reduced GMVs and poorer cognition, whereas no significant structural paths were identified in MDD.
IR markers and leptin were the strongest positive contributors to the metabolism factor in both the whole sample and the BD group. The brain regions most affected encompassed areas central to cognitive and emotional regulation, characterized by a high density of insulin and leptin receptors.
Conclusions
These findings highlight the role of IR and leptin in shaping cognition in mood disorders and underscore the potential of insulin-related pathways as therapeutic targets, especially in BD with metabolic comorbidities.
